• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract PR03: Targeting multiple cell cycle regulatory points for the prevention of triple-negative breast cancer
Conclusions: These studies demonstrate that dinaciclib alone or the combination therapy of LG100268 and dinaciclib causes inhibition of premalignant cell growth and delayed ER-negative mammary tumorigenesis in SV40 Tag mice. While an additive effect of dinaciclib and LG100268 was observed in vitro, the in vivo combination therapy was not significantly more effective than dinaciclib treatment alone. Future studies should investigate different combinations of dosages of dinaciclib and LG100268 in vivo. These studies were supported by an NCI/NIH R25T grant (R25CA057730, BL) and Susan G. Komen for the Cure Promise grant (KG081...
Source: Cancer Prevention Research - October 2, 2015 Category: Cancer & Oncology Authors: Litzenburger, B. C., Uray, I. P., Hill, J., Zhang, J., Mazumdar, A., Brown, P. H. Tags: Combinatorial Approaches to Chemoprevention: Oral Presentations - Proffered Abstracts Source Type: research